VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys

VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of disease burden in the world and is highly correlated with chronic elevations of LDL-C. LDL-C-lowering drugs, such as statins or monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9), are known t...

Full description

Bibliographic Details
Main Authors: Madeline M. Vroom, Hanxin Lu, Maggie Lewis, Brett A. Thibodeaux, Jeanne K. Brooks, Matthew S. Longo, Martina M. Ramos, Jaya Sahni, Jonathan Wiggins, Justin D. Boyd, Shixia Wang, Shuang Ding, Michael Hellerstein, Valorie Ryan, Peter Powchik, Jean-Cosme Dodart
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Journal of Lipid Research
Subjects:
atherosclerosis
atherosclerotic cardiovascular disease
PCSK9 vaccine
hyperlipidemia
PCSK9 inhibitor
hypercholesterolemia
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227524000026

Internet

http://www.sciencedirect.com/science/article/pii/S0022227524000026

Similar Items